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Conclusions:  Low dose radiotherapy provides effect palliation 
of distressing symptoms resulting from cutaneous KS with 
acceptable toxicity. 
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Purpose: Consider a 2x2x1.5 cm basal cell cancer invading right 
medial canthus periocular embryonic fusion plane. Usual 
techniques fail: an irregular PTV 4x4x2.5 cm deep, a concave 
surface, a deep tumour, and adjacent ocular structures. 
Oculoplastics/Mohs risk enucleation. Electrons with an internal 
eye shield require bolus and limit energy to 9 MeV. High energy 
conformal RT risks medial retinal damage. Systemic agents may 
palliate but do not cure. We describe low energy electron RT (e-
) with an orthovoltage (ortho) bump. “Bump” modulates energy 
by replacing some e-dose with ortho to increase surface dose and 
optimize dose distribution. Bump applies to any anatomic 
location to a depth of 2-3 cm. Bump can use e- with a tungsten 
eye shield and ortho for maximal eye-sparing. With orbit 
invaded, morbidity follows. Radiotherapy may be the best eye-
preserving option. 
Methods and Materials: Central-axis dose calculation using 
measured % depth dose were compared with central and off-
central axis dose calcs using kVDoseCalc, a dose engine validated 
in kV cone-beam and ortho therapy; and Monte Carlo for e- off-
axis dose calc. We compare conformal RT, arcs, and bump, for 
periocular cancer cases. We compared central axis data for a 4x4 
cm field with: 1) 9 MeV alone; 2) 9 MeV with 0.7 cm custom wax; 
3) 9 MeV, 80% of dose, 100 kV DXR bump, SSD 10 cm, 20% of dose; 
4) 9 MeV, 80% of dose, 200 kV DXR bump, SSD 50 cm, 20% of dose. 
Patients treated at our institution in 10 or 20 treatments 
received 8 or 16 electron treatments (prescribed to account for 
REB of electrons) and 2 or 4 photons treatments, for a total dose 
of 45 Gy in 10 fractions, or 50 Gy in 20 fractions. 
Results: For the case above tables based on measured dose give: 
Surface dose (1) 86%; (2) 90%; (3) 100%; (4) 94% 
Dmax (100%) (1) 2.0 cm; (2) 1.3 cm; (3) 2.0 cm; (4) 2.0 cm  
Dose @ 2.7 cm (1) 89%; (2) 58%; (3) 87%; (4) 91% 
Surface and depth refer to skin surface. Dose is normalized: 
Dmax = 100%. REB and geometry are not included. Comparing 
dynamic conformal ARCs, VMAT, electrons +/- bolus or tantalum 
mesh, and bump show the benefits of 9 MeV with 100-200 kV 
bump. Dose drop off is swift at ~40%/cm beyond D90%. Dose 
spares eye. Low SSD, low kV bump results in best homogeneity 
and surface dose; high kV bump gives best dose at depth. 
Patients can be scanned with a 3D printer wax replica eye shield 
to reduce artifact and enable accurate dose calculation. Actual 
patient results are illustrated with isodose distributions; for 
three clinical cases, the dose above 80% to retina was 2.5 cc for 
conformal treatment, 1.0 cc for dynamic conformal arc and < 0.5 
cc for bumps, demonstrating excellent shielding for the bump 
technique. 
Conclusions: Energy modulation with ortho and electrons can 
result in improved dose distribution. Benefits include: increased 
treatment depth, improved dose homogeneity, no bolus, 
increased shield effectiveness, and reduced penumbra; 
important when treating near the eye. 
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Purpose: Chemical exchange saturation transfer magnetic 
resonance imaging (CEST MRI) represents a novel technique for 
detecting cell death in vivo, without the need for injected 
exogenous contrast media or lengthy wait times (as with 
standard anatomical assessment of tumour response). Changes in 
CEST signal parameters corresponding to amide, amine, and 
aliphatic tissues have been suggested to correlate with necrosis. 
In this study, we sought to characterize the changes in CEST 
parameters over time to help determine the optimal time point 
to detect cell death. 
Methods and Materials: CEST MRI data were acquired from 
xenografted MDA-231 breast cancer tumours (n = 12) before and 
after injection with doxorubicin (100 mg/m2) and paclitaxel (50 
mg/m2) chemotherapy. Tumours were scanned at baseline and 
three different treatment times - 4, 8, and 12 hours after 
injection.  
Acquired data was fitted to Lorentzian shapes using a previously 
described method. The peak amplitude is measured as a unitless 
ratio of the measured signal to the CEST signal of bulk water; 
area under the curve is in units of parts per million (ppm), 
related to the resonant frequency of measured protons. Baseline 
CEST parameters were compared to parameters at each 
treatment time using two-tailed T tests with p-value for 
significance of ≤ 0.05. 
Results: For the aliphatic peak, amplitude measured 0.063 ± 
0.009 at baseline, 0.066 ± 0.009 at four hours, 0.095 ± 0.013 at 
8 hours, and 0.065 ± 0.019 at 12 hours post-injection; only the 
change from baseline to eight hours was statistically significant 
(p = 0.02). Significant change in area under the curve (0.051 ± 
0.014 to 0.115 ± 0.015 ppm; p = 0.006) was also observed at eight 
hours post-injection but not at four or 12 hours. For the amine 
peak, significant changes in amplitude were observed at eight 
hours (p < 0.001) and 12 hours (p < 0.001) post-injection; 
amplitude change was not significant at four hours nor was any 
change in peak area at any time point. For the amide peak, no 
significant differences were seen from baseline at any time point 
for peak amplitude or area. 
Conclusions: Our results suggest that eight hours after injection 
of chemotherapy may represent the optimal time to measure cell 
death using CEST MRI, as significant changes were observed in 
aliphatic and amine peak amplitudes at this time point. 
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Purpose: Tumour hypoxia is an adverse prognostic factor in many 
cancers. 18F-FAZA is a hypoxia tracer, which can provide a non-
invasive method of hypoxia imaging with PET, but has not been 
widely studied in NSCLC. This study aims to evaluate the 
feasibility and potential benefits of using 18F-FAZA-PET scans to 
assess NSCLC tumour hypoxia.  
Methods and Materials: Thirteen of the planned 20 patients with 
Stage II – III NSCLC are included thus far in this prospective study 
by imaging with FAZA-PET before initiation of radical chemo- 
radiotherapy. Patients were imaged two hours post-injection 
with FAZA. Attenuation correction was performed using a helical 
computed tomography (hCT) for respiratory gated PET (gPET). 
The exhale bin was used for analysis for the purpose of this study. 
The hypoxic volume (HV) was defined as all voxels within the 
tumour with standard uptake value (SUV) more than three 
standard deviations from the mean values obtained from muscle 
SUV as defined by Mortensen et al. 2012. The Tmax/Mmean ratio 
was defined as maximum tumour SUV divided by the mean 
erector spinae muscle SUV. The hypoxic fraction (HF) was 
determined by dividing the HV by the entire gross tumour volume 
(GTV). Pearson correlation (rho) was performed to evaluate 
whether some of these metrics are correlated.  
Results: A hypoxic volume (HV) in the primary tumour was 
identified in 12 patients (92.3%). The hypoxic fraction (HF) 
